New hope for Parkinson's: drug infusion studied in earlier advanced patients
NCT ID NCT07227896
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at how well the drug Foslevodopa/Foscarbidopa works for people with advanced Parkinson's disease who are still in the earlier phases of that stage. About 100 adults will receive the drug as a continuous infusion under the skin for up to 6 months. Researchers will track changes in 'off' time (when symptoms return) and quality of life through questionnaires.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Foslevodopa/Foscarbidopa (a drug combination given as a continuous infusion under the skin)
What this could lead to
If successful, this could show that starting this treatment earlier in advanced Parkinson's helps reduce 'off' time and improve daily function.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It's also small (100 people) and short (6 months), so benefits may not be clear or lasting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Boston Medical Center Health System
Boston, Massachusetts, 02118, United States